»
Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse
 
 

Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse, 1st Edition

 
Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse, 1st Edition,Linda P. Dwoskin,ISBN9780124201187
 
 
 

Advances in Pharmacology

L Dwoskin   

Academic Press

9780124201187

9780124201774

656

229 X 152

This new volume of Advances in Pharmacology presents the emerging targets and therapeutics in the treatment of psychostimulant abuse.

Print Book + eBook

USD 307.20
USD 512.00

Buy both together and save 40%

Print Book

Hardcover

In Stock

Estimated Delivery Time
USD 256.00

eBook
eBook Overview

DRM-free included formats : EPUB, Mobi (for Kindle), PDF

VST (VitalSource Bookshelf) format

USD 256.00
Add to Cart
 
 

Key Features

  • Contributions from the best authors in the field
  • An essential resource for pharmacologists, immunologists, and biochemists

Description

This new volume of Advances in Pharmacology presents the emerging targets and therapeutics in the treatment of psychostimulant abuse. With a variety of chapters and the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike.

Readership

Pharmacologists, immunologists, and biochemists

Linda P. Dwoskin

Affiliations and Expertise

Pharmaceutical Education, College of Pharmacy, University of Kentucky, Lexington, KY, USA

Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse, 1st Edition

Preface
Contributors
Chapter One: Glial Modulators as Potential Treatments of Psychostimulant Abuse
Abstract

1 Introduction

2 Molecular Biology and Physiology of the Glia

3 In Vivo Evidence that Modulating Glia and Neuroinflammation Provide Pharmacotherapeutic Possibilities for Psychostimulant Abuse

4 Ongoing or Planned Clinical Studies Examining Glial Modulators in the Treatment of Psychostimulant Abuse

5 Conclusion

Conflict of Interest

Chapter Two: The Vesicular Monoamine Transporter-2
Abstract

1 Methamphetamine Addiction

2 Methamphetamine: Mechanism of Action

3 Identification and Classification of Vesicular Monoamine Transporters

4 VMAT2 Function

5 VMAT2 Binding Sites

6 Aberrant VMAT2 Expression and Function

7 Conclusion

Conflict of Interest

Acknowledgments

Chapter Three: Customizing Monoclonal Antibodies for the Treatment of Methamphetamine Abuse
Abstract

1 Introduction

2 METH Mechanisms of Action, Toxicity, and Current Therapies

3 Therapeutic Monoclonal Antibodies to Counteract METH Effects

4 Predicting Therapeutic Effectiveness

5 METH Metabolism and Pharmacokinetics: Choosing the Appropriate Animal Testing Model

6 The Role of Affinity, Binding Capacity, and In Vivo Modifications in mAb Function

7 Hapten Design for Improved Target Specificity and mAb Functionality

8 Relationship Between Hapten Structure and mAb Function: Application to Other Antibody Forms

9 Antibody Form and Duration of Action

10 Conclusion

Conflict of Interest

Acknowledgments

Chapter Four: Monoamine Transporter Inhibitors and Substrates as Treatments for Stimulant Abuse
Abstract

1 Introduction

2 Operant Behavior in Medication Development

3 Monoamine Transporters as Molecular Targets for Medication Development

4 Evaluation of Monoamine Transporter Inhibitors and Substrates on Abuse-Related Effects of Psychostimulants

5 Conclusion

Conflict of Interest

Acknowledgments

Chapter Five: Bupropion and Bupropion Analogs as Treatments for CNS Disorders
Abstract

1 Introduction

2 Metabolism of Bupropion

3 Mechanism of Bupropion Therapeutic Properties

4 Animal Behavioral Studies of Bupropion

5 Clinical Studies with Bupropion

6 Bupropion nAChR Binding Site

7 Bupropion and Hydroxybupropion Analog Clinical Development

8 Conclusion

Conflict of Interest

Acknowledgments

Chapter Six: The Role of Guanfacine as a Therapeutic Agent to Address Stress-Related Pathophysiology in Cocaine-Dependent Individuals
Abstract

1 Introduction

2 Guanfacine as a Medication for Substance Abuse Compared with Other Alpha-2 Adrenergic Agonists

3 Other Potential Anxiolytics and Cognitive Enhancers

4 Long-Term Maintenance of Guanfacine

5 Conclusion

Conflict of Interest

Chapter Seven: Beyond Small-Molecule SAR
Abstract

1 Introduction

2 D3-Selective Drug Design Using Small-Molecule SAR

3 Clinical Studies Targeting the D3 Receptor in the Treatment of Addiction

4 The Structural Basis of D3 over D2 Receptor Selectivity and the Future of Rational Drug Design for D3 Receptor-Selective Ligands

5 Conclusion

Conflict of Interest

Acknowledgments

Chapter Eight: Dopamine D4 Receptors in Psychostimulant Addiction
Abstract

1 Introduction

2 DRD4 and Psychostimulant Addiction

3 Conclusion

Conflict of Interest

Acknowledgments

Chapter Nine: Sigma (s) Receptors as Potential Therapeutic Targets to Mitigate Psychostimulant Effects
Abstract

1 Introduction

2 Background on s Receptors

3 Cocaine and s Receptors

4 Methamphetamine and s Receptors

5 Clinical Implications

6 Conclusion

Conflict of Interest

Acknowledgments

Chapter Ten: Mixed Kappa/Mu Partial Opioid Agonists as Potential Treatments for Cocaine Dependence
Abstract

1 Introduction

2 Opioids Used to Treat Drug and Alcohol Dependence: Preclinical and Clinical Evidence

3 Mechanistic and In Vitro Characterization of Mixed µ/? Agonists

4 Conclusion

Conflict of Interest

Acknowledgments

Chapter Eleven: The Combination of Metyrapone and Oxazepam for the Treatment of Cocaine and Other Drug Addictions
Abstract

1 Introduction

2 Stress and Addiction

3 Cocaine and Benzodiazepines

4 Stress and Cocaine Reinforcement

5 Stress and Relapse

6 Rationale for Testing Drug Combinations

7 Our Hypothesis Changes

8 Medial Prefrontal Cortex and Cocaine

9 Neurosteroids and the Combination of Metyrapone and Oxazepam

10 Conclusion

Conflict of Interest

Chapter Twelve: Salvinorin A Analogs and Other Kappa-Opioid Receptor Compounds as Treatments for Cocaine Abuse
Abstract

1 Introduction

2 Kappa-Opioid Receptors and the Endogenous Opioid System

3 Kappa-Opioid Regulation of Dopamine Systems

4 Effects of Drugs of Abuse on the Kappa-Opioid System

5 Effects of Kappa-Opioid Receptor Agonists on Drug Addiction

6 Animal Studies with Sal A

7 Effects of Sal A on Depression

8 Antidepressive Effects of Sal A

9 Prodepressive Effects of Sal A

10 Signaling Pathways Regulated by Sal A

11 Pharmacokinetics of Sal A

12 Sal A Analogs

13 Conclusion

Conflict of Interest

Chapter Thirteen: Nicotinic Receptor Antagonists as Treatments for Nicotine Abuse
Abstract

1 Introduction

2 Current Smoking Cessation Therapies that Target nAChRs

3 Emerging Potential Therapeutics for Treatment of Tobacco Dependence

4 Small-Molecule Surrogates of a-CtxMII as Smoking Cessation Agents

5 Monoquaternary Ammonium Salts Derived from N-Methylnicotinium Ion as Nicotinic Receptor Antagonists

6 Conclusion

Conflict of Interest

Acknowledgments

Chapter Fourteen: New Directions in Nicotine Vaccine Design and Use
Abstract

1 Introduction

2 Status of First-Generation Nicotine Vaccines

3 Limitations of First-Generation Nicotine Vaccines

4 Limitations of Vaccination as a General Strategy for Treating Nicotine Addiction

5 Design of Nicotine Vaccines

6 Strategies for Improving Vaccine Efficacy

7 Alternatives to Vaccination

8 Translational Considerations

9 Conclusion

Conflict of Interest

Acknowledgments

Chapter Fifteen: Bath Salts, Mephedrone, and Methylenedioxypyrovalerone as Emerging Illicit Drugs That Will Need Targeted Therapeutic Intervention
Abstract

1 Introduction

2 PIA Analogs: Nomenclature and Pharmacological Assays

3 Cathinone Analogs: Historical Perspectives

4 Amphetamine (i.e., Phenylisopropylamine) Analogs

5 Synthetic Cathinones: Specific Agents

6 Synthetic Cathinones: Mechanisms of Action and Behavioral Studies

7 Synthetic Cathinones: Human Studies

8 Conclusion

Conflict of Interest

Acknowledgments

Index

 
 
Free Shipping
Shop with Confidence

Free Shipping around the world
▪ Broad range of products
▪ 30 days return policy
FAQ

Contact Us